 Home > Biochemistry News > Biotechnology News > Ascentage Pharma and Pfizer reached a clinical cooperation agreement to jointly advance the clinical development of APG-2575 combined with CDK4/6 inhibitor Aiboxin® for the treatment of metastatic ER-positive HER2-negative breast cancer

Ascentage Pharma and Pfizer reached a clinical cooperation agreement to jointly advance the clinical development of APG-2575 combined with CDK4/6 inhibitor Aiboxin® for the treatment of metastatic ER-positive HER2-negative breast cancer

 Last Update: 2022-02-27
 Source: Internet
 Author: User

Tags

new 12s

magnesium cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Suzhou, China and Rockville, Maryland, U.

Under the terms of the collaboration, Ascentage Pharma will conduct the study and Pfizer will provide the palbociclib required for the study

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma.

"This is the first clinical study of APG-2575 for the treatment of solid tumors, and we have obtained clinical licenses for this study in the United States and China

About Ascentage Pharma

Ascentage Pharma is an original innovative drug research and development enterprise in the clinical development stage based in China and facing the world

Ascentage Pharma has a self-constructed protein-protein interaction targeted drug design platform, which is at the forefront of the global research and development of new drugs for apoptosis pathways

With strong R&D capabilities, Ascentage Pharma has deployed intellectual property rights globally, and has partnered with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.

Forward-Looking Statements

Forward-looking statements made herein relate only to events or information as of the date on which they are made

Source: Ascentage Pharma

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.